A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRAS Q61R/K/L Mutant Melanoma (TraMel-WT).
Saved in:
| Title: | A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRAS Q61R/K/L Mutant Melanoma (TraMel-WT). |
|---|---|
| Authors: | Awada, Gil1 (AUTHOR) gil.awada@uzbrussel.be, Schwarze, Julia Katharina1 (AUTHOR) juliakatharina.schwarze@uzbrussel.be, Tijtgat, Jens1 (AUTHOR) jens.tijtgat@uzbrussel.be, Fasolino, Giuseppe2 (AUTHOR) giuseppe.fasolino@uzbrussel.be, Everaert, Hendrik3 (AUTHOR) hendrik.everaert@uzbrussel.be, Neyns, Bart1 (AUTHOR) bart.neyns@uzbrussel.be, Moulin, Alexandre (AUTHOR), Michielin, Olivier (AUTHOR), Baldi, Alfonso (AUTHOR) |
| Source: | Cancers. May2021, Vol. 13 Issue 9, p2010-2010. 1p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 20726694 |
|---|---|
| DOI: | 10.3390/cancers13092010 |
